(Reuters) - Questions about Avandia erupted in May when the New England
Journal of Medicine published an analysis that said the widely
used drug raised heart-attack risk by 43 percent. The FDA and
Glaxo say other evidence conflicts with the finding, and the
agency is weighing whether any regulatory action is needed.
The advisory panel will discuss the cardiovascular risks of
the class known as thiazolidinediones, "with a focus on
rosiglitazone, as presented by FDA and GlaxoSmithKline," the
FDA said. Rosiglitazone is the generic name of Avandia.
Read more at Reuters.com Government Filings News
Journal of Medicine published an analysis that said the widely
used drug raised heart-attack risk by 43 percent. The FDA and
Glaxo say other evidence conflicts with the finding, and the
agency is weighing whether any regulatory action is needed.
The advisory panel will discuss the cardiovascular risks of
the class known as thiazolidinediones, "with a focus on
rosiglitazone, as presented by FDA and GlaxoSmithKline," the
FDA said. Rosiglitazone is the generic name of Avandia.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment